Latest news
{{'2026-02-03T16:38:42Z' | dateFormatFilter}}
Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
{{'2026-02-03T16:37:32Z' | dateFormatFilter}}
Novo Nordisk releases 2026 sales and operating profit outlook
{{'2026-02-02T15:43:01Z' | dateFormatFilter}}
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
